Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors
HARRISON, NY / ACCESSWIRE / August 12, 2020 / Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and...